New biomarkers were identified that can help to predict the response of colorectal cancer treatment with cetuximab or 5-fluorouracil (5-FU). A large biobank (OncoTrack) with omics data comparing wild-type tumors and derived tumor model has been created, which can provide a resource for the advance understanding of CRC. Colorectal cancer (CRC) is characterized by its heterogeneous nature and can be classified into distinct molecular groups. However, the clinical utility of this classification is still not demonstrated.
Notably, only a fraction of tumor responds to chemotherapeutic agents like cetuximab, 5-fluorouracil (5-FU), irinotecan or oxaliplatin. This demands the need of precision oncology and an advance molecular understanding of the disease to imply accurate therapeutic measures. Although, BRAF, KRAS and NRAS mutations are routinely used as predictive markers of resistance to…
